BiotechTube

BMS-986165 + Rosuvastatin

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autoimmune Diseases

Conditions

Autoimmune Diseases, Inflammatory Diseases

Trial Timeline

Feb 2, 2017 → Mar 27, 2017

NCT ID
NCT03044873

About BMS-986165 + Rosuvastatin

BMS-986165 + Rosuvastatin is a phase 1 stage product being developed by Bristol Myers Squibb for Autoimmune Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT03044873. Target conditions include Autoimmune Diseases, Inflammatory Diseases.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03044873Phase 1Completed

Competing Products

20 competing products in Autoimmune Diseases

See all competitors
ProductCompanyStageHype Score
SatralizumabChugai PharmaceuticalPhase 3
77
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
33
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
33
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
52
Enteric-coated Mycophenolate SodiumNovartisPhase 3
77
Ianalumab + PlaceboNovartisPhase 3
77
VAY736NovartisPhase 2/3
65
remibrutinibNovartisPhase 1
33
RO7049665RochePhase 2
52
rituximab (Mabthera®) + PlaceboRochePhase 3
77
NovoMix 30 + Tablet treatmentNovo NordiskPre-clinical
22
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1) + Placebo injection (Period 1) + Anakinra 100Mg/0.67Ml Inj Syringe (Period 2) + Placebo injection (Period 2)Swedish Orphan BiovitrumPhase 2
51
branebrutinib + abatacept + branebrutinib placeboBristol Myers SquibbPhase 2
51
BMS-986165Bristol Myers SquibbPhase 1
32
NivolumabBristol Myers SquibbPhase 1
32
Fludarabine + Cyclophosphamide + TocilizumabBristol Myers SquibbPhase 1
32
SAR445088SanofiPhase 1
32
BIVV020SanofiPhase 1
32
rilzabrutinibSanofiPhase 2
51
rilzabrutinib + placeboSanofiPhase 3
76

Other Products from Bristol Myers Squibb

DeucravacitinibApproved
84
Aripiprazole + Olanzapine + HaloperidolApproved
84
Irbesartan + CiprofibrateApproved
84
Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved
84
deucravacitinibApproved
84